OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients
Simeon Schietzel, Manuel Anderegg, Andreas Limacher, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002036-e002036
Open Access | Times Cited: 66
Simeon Schietzel, Manuel Anderegg, Andreas Limacher, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002036-e002036
Open Access | Times Cited: 66
Showing 1-25 of 66 citing articles:
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
Rona Smith, Rachel Jones, Ulrich Specks, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 7, pp. 937-944
Open Access | Times Cited: 61
Rona Smith, Rachel Jones, Ulrich Specks, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 7, pp. 937-944
Open Access | Times Cited: 61
Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews
Kay Choong See
Vaccines (2022) Vol. 10, Iss. 5, pp. 800-800
Open Access | Times Cited: 33
Kay Choong See
Vaccines (2022) Vol. 10, Iss. 5, pp. 800-800
Open Access | Times Cited: 33
Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study
Victoria Furer, Tali Eviatar, Tal Freund, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 11, pp. 1594-1602
Closed Access | Times Cited: 30
Victoria Furer, Tali Eviatar, Tal Freund, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 11, pp. 1594-1602
Closed Access | Times Cited: 30
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study
Daniel Mrak, Elisabeth Simader, Daniela Sieghart, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 12, pp. 1750-1756
Open Access | Times Cited: 28
Daniel Mrak, Elisabeth Simader, Daniela Sieghart, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 12, pp. 1750-1756
Open Access | Times Cited: 28
Effect of DMARDs on the immunogenicity of vaccines
Yannick van Sleen, Kornelis S. M. van der Geest, Anke Huckriede, et al.
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 9, pp. 560-575
Closed Access | Times Cited: 18
Yannick van Sleen, Kornelis S. M. van der Geest, Anke Huckriede, et al.
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 9, pp. 560-575
Closed Access | Times Cited: 18
Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)
María Eva Mingot‐Castellano, Mariana Canaro Hirnyk, Blanca Sánchez‐González, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6422-6422
Open Access | Times Cited: 15
María Eva Mingot‐Castellano, Mariana Canaro Hirnyk, Blanca Sánchez‐González, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6422-6422
Open Access | Times Cited: 15
Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies
G. Olivieri, Donato Amodio, Emma Concetta Manno, et al.
Vaccine (2025) Vol. 51, pp. 126853-126853
Open Access
G. Olivieri, Donato Amodio, Emma Concetta Manno, et al.
Vaccine (2025) Vol. 51, pp. 126853-126853
Open Access
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
Felix Kartnig, Daniel Mrak, Elisabeth Simader, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 292-300
Open Access | Times Cited: 22
Felix Kartnig, Daniel Mrak, Elisabeth Simader, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 292-300
Open Access | Times Cited: 22
Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab
Victoria Furer, Tali Eviatar, Devy Zisman, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 901-901
Open Access | Times Cited: 20
Victoria Furer, Tali Eviatar, Devy Zisman, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 901-901
Open Access | Times Cited: 20
Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy
Daniel Sidler, Alexander Born, Simeon Schietzel, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002166-e002166
Open Access | Times Cited: 16
Daniel Sidler, Alexander Born, Simeon Schietzel, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002166-e002166
Open Access | Times Cited: 16
Glucocorticoids in the treatment of IgG4-related disease—Prospects for new international treatment guidelines
Hajime Yoshifuji, Hisanori Umehara
Modern Rheumatology (2022) Vol. 33, Iss. 2, pp. 252-257
Closed Access | Times Cited: 14
Hajime Yoshifuji, Hisanori Umehara
Modern Rheumatology (2022) Vol. 33, Iss. 2, pp. 252-257
Closed Access | Times Cited: 14
Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis
Dóra Németh, Hajnalka Vágó, László Tóthfalusi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Dóra Németh, Hajnalka Vágó, László Tóthfalusi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study
Merav Heshin‐Bekenstein, Amit Ziv, Nataša Toplak, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 819-819
Open Access | Times Cited: 8
Merav Heshin‐Bekenstein, Amit Ziv, Nataša Toplak, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 819-819
Open Access | Times Cited: 8
Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia
Jolene Yin Ling Fu, Muhammad Harith Pukhari, Maria Kahar Bador, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 844-844
Open Access | Times Cited: 7
Jolene Yin Ling Fu, Muhammad Harith Pukhari, Maria Kahar Bador, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 844-844
Open Access | Times Cited: 7
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)
Alexandra Griessbach, Frédérique Chammartin, Irène A. Abela, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 4
Open Access | Times Cited: 7
Alexandra Griessbach, Frédérique Chammartin, Irène A. Abela, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 4
Open Access | Times Cited: 7
The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA)
Martina Frodlund, Per Nived, Katerina Chatzidionysiou, et al.
Vaccine (2023) Vol. 41, Iss. 20, pp. 3247-3257
Open Access | Times Cited: 7
Martina Frodlund, Per Nived, Katerina Chatzidionysiou, et al.
Vaccine (2023) Vol. 41, Iss. 20, pp. 3247-3257
Open Access | Times Cited: 7
Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?
David Baker, Amy MacDougall, Angray S. Kang, et al.
Clinical & Experimental Immunology (2021) Vol. 207, Iss. 3, pp. 263-271
Open Access | Times Cited: 17
David Baker, Amy MacDougall, Angray S. Kang, et al.
Clinical & Experimental Immunology (2021) Vol. 207, Iss. 3, pp. 263-271
Open Access | Times Cited: 17
Hybrid and vaccine‐induced immunity against SAR‐CoV ‐2 in MS patients on different disease‐modifying therapies
Ilya Kister, Ryan Curtin, Jinglan Pei, et al.
Annals of Clinical and Translational Neurology (2022) Vol. 9, Iss. 10, pp. 1643-1659
Open Access | Times Cited: 11
Ilya Kister, Ryan Curtin, Jinglan Pei, et al.
Annals of Clinical and Translational Neurology (2022) Vol. 9, Iss. 10, pp. 1643-1659
Open Access | Times Cited: 11
Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy
Davide Firinu, Giuseppe Fenu, Giuseppina Sanna, et al.
Journal of Autoimmunity (2022) Vol. 131, pp. 102848-102848
Open Access | Times Cited: 10
Davide Firinu, Giuseppe Fenu, Giuseppina Sanna, et al.
Journal of Autoimmunity (2022) Vol. 131, pp. 102848-102848
Open Access | Times Cited: 10
Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital
Cristina Costa, Gitana Scozzari, Enrica Migliore, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1031-1031
Open Access | Times Cited: 10
Cristina Costa, Gitana Scozzari, Enrica Migliore, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1031-1031
Open Access | Times Cited: 10
Role of rituximab in the treatment of systemic sclerosis: A literature review
Hajime Yoshifuji, Keina Yomono, Yasuhiko Yamano, et al.
Modern Rheumatology (2023) Vol. 33, Iss. 6, pp. 1068-1077
Closed Access | Times Cited: 5
Hajime Yoshifuji, Keina Yomono, Yasuhiko Yamano, et al.
Modern Rheumatology (2023) Vol. 33, Iss. 6, pp. 1068-1077
Closed Access | Times Cited: 5
A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy
Nika Kianfar, Shayan Dasdar, Maryam Daneshpazhooh, et al.
Experimental Dermatology (2023) Vol. 32, Iss. 7, pp. 934-944
Open Access | Times Cited: 5
Nika Kianfar, Shayan Dasdar, Maryam Daneshpazhooh, et al.
Experimental Dermatology (2023) Vol. 32, Iss. 7, pp. 934-944
Open Access | Times Cited: 5
Importance of Vaccination against SARS-CoV-2 in Patients with Interstitial Lung Disease Associated with Systemic Autoimmune Disease
Natalia Mena‐Vázquez, Aimara García-Studer, M. Rojas-Giménez, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 9, pp. 2437-2437
Open Access | Times Cited: 9
Natalia Mena‐Vázquez, Aimara García-Studer, M. Rojas-Giménez, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 9, pp. 2437-2437
Open Access | Times Cited: 9
Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy
Ashley J. Priddey, Michael Chen‐Xu, Daniel J Cooper, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 1
Ashley J. Priddey, Michael Chen‐Xu, Daniel J Cooper, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 1
Bruno Fattizzo, Alexander Röth, Catherine M. Broome, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 789-791
Open Access | Times Cited: 1
